McDaid et al. used the clinically approved anti-EGFR antibody (i.e., Cetuximab) for targeting PLGA NPs in order to lower off-target cytotoxicity and enhance drug efficacy in EGFR-resistant PC 202 The conjugation-induced targeting and apoptosis were demonstrated in several different cancer cell models, indicating a generalizable approach for nano-enabled enhanced drug efficacy. This evidence concerns the gene EGFR and cancer.